| Title |
Peginterferon-α-2a (40kD) Plus Ribavirin
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/00003495-200464240-00009 |
| Pubmed ID | |
| Authors |
Greg L. Plosker, Gillian M. Keating |
| Abstract |
Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen is not established in the more difficult-to-treat population with HIV-HCV co-infection, much of the data in this clinical setting have been derived from studies evaluating peginterferon-alpha-2a (40kD) [Pegasys] plus ribavirin (Copegus), most notably the APRICOT (AIDS Pegasys Ribavirin International Co-Infection Trial) and the ACTG (AIDS Clinical Trial Group) A5071 study. In particular, results of APRICOT - the largest study conducted to date with a pegylated interferon plus ribavirin in patients with HIV-HCV co-infection - indicate that a substantial proportion of patients will achieve sustained virological response (SVR) at week 72 when these drugs are administered for 48 weeks in an appropriate dosage regimen. In general, the tolerability profile of peginterferon-alpha-2a plus ribavirin in APRICOT was similar to that previously reported in patients with HCV mono-infection. |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 4% |
| Other | 3 | 3% |
| Student > Bachelor | 2 | 2% |
| Student > Postgraduate | 2 | 2% |
| Librarian | 1 | <1% |
| Other | 4 | 3% |
| Unknown | 99 | 85% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Agricultural and Biological Sciences | 2 | 2% |
| Business, Management and Accounting | 1 | <1% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 101 | 87% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2015.
All research outputs
#5,447,195
of 25,374,917 outputs
Outputs from Drugs
#833
of 3,464 outputs
Outputs of similar age
#39,051
of 188,986 outputs
Outputs of similar age from Drugs
#282
of 1,509 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 1,509 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.